



**RECEPTOL® ORAL SPRAY SHIELD FOR CORONA VIRUS PROPOSED  
TREATMENT AND PREVENTION AS DEMONSTRATED IN AIDS**  
INDIAN SOLUTION TO GLOBAL HEALTH PROBLEM

Dr. Pawan Saharan MS Ph.D.(USA) [drpawan@biomix.in](mailto:drpawan@biomix.in), [www.biomix.in](http://www.biomix.in), +91-8291084108

A new coronavirus, declared as Global Health Emergency (PHEIC) by WHO, 2019-nCoV was first identified in Wuhan, the capital of China's Hubei province, after people developed SARS like pneumonia. The incubation period (time from exposure to the development of symptoms) of the virus is 2-10 days and can be contagious during this time. Symptoms include fever, coughing, and breathing difficulties. Without a clear cause of 2019-nCoV, treatments with existing vaccines is not effective.

1st PHEIC was declared by WHO for Swine Flue (H1N1 Influenzas) in 2009 with 284,500 death with 763 million cases reported in 214 countries and was successfully contained by Receptol® used at 3 domestic & international airports in Mumbai by Mumbai International Airports Ltd. The

Patented Receptol® oral spray (USA Patent # US 9,249,188 B2) is a new Immunity Drug (NID) providing mode of action in a vaccine like manner with active immunity, can be used for treatment and as preventative vaccine in dealing with current 2019-nCoV epidemic.

Receptol® consists of cell to cell communicator Nano informational peptides (Radha108) & proline-Rich Polypeptides (PRPs) from colostrum, Mother's 1st milk after the birth of the child or calf.

Numerous Studies have shown that Receptol® spray will deliver nano peptide crossing blood brain barrier and have great effectiveness in treating many immunity disease including all viral infections. As a natural product, Radha-108 Nanopeptides have no side effects which can be taken safely by all age and are not species specific. Receptol® showed great effectiveness in treatment of retrovirus such as HIV, Swine Flu and SARS like conditions caused by Coronavirus. An accelerated, prospective Phase III

global efficacy and safety studies for Receptol® (containing API of Radha 108 Nanopeptides) was conducted for HIV Positive patients with 10 years follow up showed significant resolution of all symptoms and pharmacological effects with low to NIL Viral Load.

Once RADHA108 series get absorbed in the blood stream through buccal mucosa or transdermal route and crosses the Blood Brain Barrier (BBB), they act on Pituitary gland in brain and cell to cell communicator informational proteins (RADHA108) in RECEPTOL® will active in mitigating cell fusion. RADHA108 series has shown to dock on glycoprotein receptor on the cell surface and thus closing doors and windows for viral entry into the cell surface & immune cells in particular.

Coronaviruses is enveloped positive- RNA viruses characterized by club-like spikes that project from their surface. It has unusually large RNA genome, four main structural proteins. spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins as virus particles. S protein is cleaved by a host cell furin-like protease into two separate polypeptides noted S1 and S2. The initial attachment of the virion to the host cell is initiated by interactions between the S protein and its receptor.

The S-protein/receptor interaction is the primary determinant for a coronavirus to infect a host species and also governs the tissue tropism of the virus. Receptol® nano-peptides can block the attachment of S protein like In case of well-studied mode of action in treatment of retrovirus infection such as HIV.


Receptol® oral spray invented via Dr Pawan Saharan, Founder, Biomix USA, Australia and INDIA ( [www.biomix.in](http://www.biomix.in)) can be an answer to prevent & treat current epidemic of 2019-nCoV as its Mode of Action is similar to that of AIDS for which global studies with 10 years follow is done.

Receptol®'s RADHA108 series nano-peptide will not only dock on S glycoprotein receptor on the cell surface to mitigate cell fusion closing doors and windows for all viral entry but will also stimulate the maturation of immature thymocytes into either helper or suppressor T cells, T help cells will help produce antibodies against 2019nCoV, Suppressor T cells, on the other hand, deactivate other lymphocytes after an infection has been cleared to avoid damage to healthy tissues. Receptol® will help to produce memory T cells, in order to expedite the production of antibodies for future infection in all human hosts.


## Common Mode of Action

Electron Micrograph Showing both HIV & Coronavirus unable to infect cells via Radha108 Nano-peptides Competitive inhibition on Cell surface with viral lock down

Receptol® Mode of Action in HIV/ AIDS



Receptol® Mode of Action in Coronavirus Scenario



## References:

1. "Health for All via Receptol-A Paradigm shift in healthcare: treatment to prevention" Book released by Health Minister of India 18, Sept 2014
2. Paradigm shift in discovery & secretion of biosimilars via path breaking Innovation, Pawan Saharan, Biomix Network Inc. USA 5th European Biosimilars Congress, June 27-29,2016, Valencia, Spain
3. United States Patent : Pawan Saharan, Mammalian Colostrum derived Nano peptides for broad spectrum viral and recurrent infection with a method of isolation thereof,
4. Granted product patent #: US 9,249,188 B2 (Year 2016) & US 8518454 B2 (Year 2013). Proceedings of 5th European Biosimilars Congress,Valencia, Spain, June 27-29, 2016 Published in American Journal of bioanalysis & biomedicine, Paradime shift in discovery & secretion of Biosimilars via path breaking innovation: Radha108 Nanopeptides extracted from bovine Colostrum by Pawan Saharan, JBABM, ISSN:1948-593x, Volume 8, Issue 3, 2016
5. Granitov, VM et al...Usage of RECEPTOL in treatment of HIV – Infected patients. Russian Journal of HIV AIDS and Related Problems 2002, 1, 79-80
6. World Health Organization. Progress on global access to HIV antiretroviral therapy: a report on "3 by 5" and beyond. 2006.
7. Brahmhatt H, Kigozi G, Wabwire-Mangen F, Serwadda D, Lutalo T, Nalugoda F, Sewankambo N, Kiduggavu M, Wawer M, Gray R. Mortality in HIV-infected and 11 uninfected children of HIV-infected and uninfected mothers in rural Uganda. J Acquire

Immune Defic Snyder 2006;41(4):504-8.

8. Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. *Lancet* 2004; 364(9441):1236-43.
9. Taha TE, Dallabetta GA, Canner JK, Chipangwi JD, Liomba G, Hoover DR, Miotti PG. The effect of human immunodeficiency virus infection on birth weight and infant and child mortality in urban Malawi. *Int J Epidemiol* 1995; 24(5):102
10. Janusz M., Staroscik K., Zimecki M., Wieczorek Z., Lisowski J., Aproline-rich polypeptide (PRP) with immunoregulatory properties isolated from ovine colostrums. *Archivum immunologic therapies experimentalis (Warszawa)* 34(4): 427-436 (1986).
11. Wieczorek Z., Zimecki M., Spiegel K., Lisowski J., Janusz M., Differentiation of T-Cells from immature precursors: identification of a target cell for a proline rich polypeptide (PRP) *Archivum immunological therapies experimentalists (Warszawa)* 37(3-4):313-322(1989).
9. Kubis A., Marcinkowska E., Janusz M., Lisowski J. Studies on mechanism of action of a proline-rich polypeptide complex (PRP): Effect on stage of cell differentiation peptides 26(11) : 2188-2192 (2005).
12. Modulation of 4HNE-mediated signaling by proline-rich polypeptides from ovine colostrums. *Journal of Molecular Neuroscience* 20(2):125-134 (2003).
13. Zibiocka A., Janusz M., Rybka K., Wirkus – Romanowska I. Kupryszewski G., Lisowski J. Cytoline inducing activity of a proline-rich polypeptide (PRP) from ovine colostrum and its active nanopeptide fragment analogs. *European Cytokine Network* 12(3) :462-467 (2001).
14. Fernandez- ortega C. Dubed M. Ruibal O. Vilarruba OL. Menendez de San Pedro JC. Navea L. Ojeda M. Arana MJ. Inhibition of in vitro HIV infection by dialyzable leucocyte extracts, *Biotherapy* 9(1-3)33-40 (1996).
15. Zimecki M,Staroscik K, Janusz M, Lisowski J, Wieczorek Z. The inhibitory activity of proline-rich polypeptide on the immune response to polyvinyl pyrrolidone (PVP). *Arch Immunol Ther Exp (Warsz)*1983;31(6):895-903.
16. Julius MH, Janusz M, Lisowski J. A colostrum protein that induces the growth and differentiation of resting B lymphocytes. *J Immunol*, 1988; 140(5):1366-371.
17. Boldogh I, Liebenthal D, Hughes TK, Juelich TL, Georgiades JA, Kruzel ML, Stanton GJ. Modulation of 4HNE-mediated signaling by a proline-rich polypeptides from ovine colostrum. *J Mol Neurosci.* 2003;20(2):125-134.
18. Pizza G, Chiodo F, Colangeli V, Gritti F, Raise E, Fudenberg HH. Preliminary observations using HIV-specific transfer factor in AIDS. *Biotherapy.* 1996;9(1-3):4-47.
19. Eggena MP, Barugahare B, Jones N, Okello M, Mutalya S, Kityo C, Mugenyi P, Cao H. Depletion of regulatory T cells in HIV infection is associated with immune activation. *J Immunol.* 2005; 174(7):4407-4414.
20. Shi M, Hao S, Chan T, Xiang J. CD4+ T cells stimulate memory CD8+ T cell expansion via acquired pMHC I complexes and costimulatory molecules, and IL-2 secretion. *J Leuco Biol*, 2006; 80(6):1354-1363.
21. Landmark study: PRPs it's clinical applications, Steven J Block, MD, International journal of integrative medicine.(Article has 44 additional ref.)
2. Lawrence HS, Borkowsky W: Transfer factor: Current status and future prospects, *Biotherapy* 9:1:5, 1996.
3. 4. Granitov, VM et al... Usage of RECEPTOL® in treatment of HIV – Infected patients.

Russian Journal of HIV AIDS and Related Problems 2002, 1, 79-80

5. World Health Organization. Progress on global access to HIV antiretroviral therapy: a report on "3 by 5" and beyond. 2006.

22. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Lai CC, et al. Int J Antimicrob Agents 2020 - Review. PMID 32081636

23. Straining the System: Novel Coronavirus (COVID-19) and Preparedness for Concomitant Disasters. Smith N and Fraser M. Am J Public Health 2020. PMID 32053389

24. Time Course of Lung Changes On Chest CT During Recovery From 2019 Novel Coronavirus (COVID-19) Pneumonia. Pan F, et al. Radiology 2020. PMID 32053470

25. The Novel Coronavirus: A Bird's Eye View. Habibzadeh P and Stoneman EK. Int J Occup Environ Med 2020 - Review. PMID 32020915 Free article.

26. COVID-19, Australia: Epidemiology Report 2 (Reporting week ending 19:00 AEDT 8 February 2020). COVID-19 National Incident Room Surveillance Team . Commun Dis Intell (2018) 2020. PMID 32050080 Free article.

27. The reproductive number of COVID-19 is higher compared to SARS coronavirus. Liu Y, et al. J Travel Med 2020. PMID 32052846

28. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team . Zhonghua Liu Xing Bing Xue Za Zhi 2020. PMID 32064853 Chinese.

29. Case of the Index Patient Who Caused Tertiary Transmission of COVID-19 Infection in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RT-PCR. Lim J, et al. J Korean Med Sci 2020. PMID 32056407 Free PMC article.

30. Potential Interventions for Novel Coronavirus in China: A Systematic Review. Zhang L and Liu Y. J Med Virol 2020 - Review. PMID 32052466

31. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? Peeri NC, et al. Int J Epidemiol 2020. PMID 32086938